骨髓中CDKN1C阳性表达在MDS和AML患者中检测的临床意义

doi:10.11904/j.issn.1002-3070.2018.02.004

实用肿瘤学杂志 ›› 2018, Vol. 32 ›› Issue (2): 112-116.doi: 10.11904/j.issn.1002-3070.2018.02.004

骨髓中CDKN1C阳性表达在MDS和AML患者中检测的临床意义

付晓英¹, 李光², 杨彩霞¹

1.宝鸡市中心医院血液科(宝鸡 721008);
2.西安市中心医院;西安市血液病研究所

收稿日期:2017-02-08 出版日期:2018-04-28 发布日期:2018-05-09
通讯作者: 付晓英,E-mail:fuxiaoying1979@163.com
作者简介:付晓英,女,(1979-),本科,主管检验师,从事骨髓检验方面的研究。
基金资助:
陕西省自然科学基金项目(编号:2013JM4016)

Clinical significance of CDKN1C positive expression in bone marrow in patients with myelodysplastic syndrome and secondary acute myeloid leukemia

FU Xiaoying¹, LI Guang², YANG Caixia¹

1.Department of Hematology,Baoji Central Hospital,Baoji 721008,China;
2.Xi′an Central Hospital,Xi′an Institute of Hematology

Received:2017-02-08 Online:2018-04-28 Published:2018-05-09

摘要/Abstract

摘要： 目的探讨骨髓中CDKN1C阳性表达在骨髓增生异常综合征(MDS)和继发性急性髓系白血病(AML)患者中检测的临床意义。方法选取125例MDS/AML患者作为研究对象,同时选取20例健康人群作为健康对照组,分析MDS/AML患者骨髓CD34⁺细胞中CDKN1C的mRNA和蛋白表达水平,比较不同CDKN1C表达水平的MDS患者生存率,采用Cox回归分析MDS和AML患者生存率影响因素,并分析治疗方法对不同CDKN1C表达水平的MDS患者生存率的影响。结果 MDS/AML患者骨髓CD34⁺细胞中CDKN1C mRNA和蛋白表达水平显著高于健康对照组,且与BM(Bone marrow)比例呈正相关(r=0.423,P=0.012);CDKN1C高表达组患者的生存率显著低于CDKN1C低表达组和CDKN1C中表达组(P＜0.05);Cox回归分析结果显示高龄、高BM比例、细胞遗传学风险差以及CDKN1C阳性显著影响MDS/AML患者生存率(P＜0.05);MDS/AML化疗的CDKN1C阳性表达组患者生存率显著低于CDKN1C阴性组患者(P＜0.05),MDS/AML化疗后造血干细胞移植(AlloSCT)的CDKN1C阳性组患者生存率显著低于CDKN1C阴性组患者(P＜0.05)。结论 MDS/AML患者骨髓中CDKN1C的表达显著增高,CDKN1C阳性表达显著影响化疗MDS/AML患者的预后生存。

关键词: CDKN1C, 骨髓增生异常综合征, 继发性急性髓系白血病, 骨髓

Abstract: Objective The aim of this study was to investigate the clinical significance of CDKN1C positive expression in bone marrow in patients with myelodysplastic syndrome and secondary acute myeloid leukemia.Methods 125 patients with MDS/AML were selected as the research subjects,and selected 20 healthy subjects as a healthy control group.The mRNA and protein expression levels of CDKN1C in CD34⁺ cells of MDS/AML patients were analyzed.The expression levels of CDKN1C were compared with those of MDS patients.The survival rate of patients with MDS and AML was analyzed by Cox regression analysis.The survival rate of MDS patients with different expression levels of CDKN1C was also analyzed.Results The expression of CDKN1C at levels of mRNA and protein in bone marrow CD34⁺ cells of MDS/AML patients were significantly higher than those in healthy controls(P＜0.05).There has a positive correction with BM(P＜0.05).The survival rate of CDKN1C high expression group was significantly lower than that in the low and mediate CDKN1C expression groups(P＜0.05).The results of Cox regression analysis showed that age,high BM count,cytogenetic difference and the positive expression of CDKN1C significantly affected the survival rate of patients with MDS/AML(P＜ 0.05);The survival rate of MDS/AML chemotherapy in the CDKN1C positive group was significantly lower than that of CDKN1C negative expression group(P＜0.05).The survival rate of MDS/AML after chemotherapy AlloSCT CDKN1C positive expression group was significantly lower than that of CDKN1C negative expression group(P＜0.05).Conclusion The expression of CDKN1C in bone marrow of MDS/AML patients was significantly increased,and the positive expression of CDKN1C significantly increased,and the positive expression of CDKN1C significantly affected the survival rate of MDS/AML patients.

Key words: CDKN1C, Myelodysplastic syndrome, Secondary acute myeloid leukemia, Bone marrow

中图分类号:

R733.3

付晓英, 李光, 杨彩霞. 骨髓中CDKN1C阳性表达在MDS和AML患者中检测的临床意义[J]. 实用肿瘤学杂志, 2018, 32(2): 112-116.

FU Xiaoying, LI Guang, YANG Caixia. Clinical significance of CDKN1C positive expression in bone marrow in patients with myelodysplastic syndrome and secondary acute myeloid leukemia[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 112-116.

参考文献

1 冯秀梅,许洪志,张婧瑶,等.再生障碍性贫血、骨髓增生异常综合征和急性髓系白血病患者CD4⁺T细胞亚群转录因子表达的变化及其临床意义[J].中国实验血液学杂志,2014,22(4):1038-1042.
2 Garcia MG.Myelodysplastic syndromes:2014 update on diagnosis,risk-stratification,and management[J].AM J Hematol,2011,86(6):490-498.
3 Greenberg PL,Tuechler H,Schanz J,et al.Revised international prognostic scoring system for myelodysplastic syndromes[J].Blood,2012,120(12):2454-2465.
4 华海应,高华强,朱文艳,等.Wilms肿瘤基因在骨髓增生异常综合征与急性白血病患者骨髓细胞中的表达及其临床意义[J].江苏医药,2015,41(20):2394-2396.
5 Ferrara F.Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?[J].Hematological Oncology,2014,32(1):1-9.
6 Bertoli S,Bories P,Béné MC,et al.Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia:long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group.[J].Haematologica,2014,99(1):46-53.
7 Craddock C,Quek L,Goardon N,et al.Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia[J].Leukemia,2013,27(5):1028-1036.
8 Schiller GJ.High-risk acute myelogenous leukemia:treatment today and tomorrow[J].Hematology,2013,2013(1):201-208.
9 Will B,Zhou L,Vogler TO,et al.Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations[J].Blood,2012,120(10):2076-2086.
10 Brenet F,Kermani P,Spektor R,et al.TGFβ restores hematopoietic homeostasis after myelosuppressive chemotherapy[J].J Exp Med,2013,210(3):623-639.
11 Pellagatti A,Benner A,Mills KI,et al.Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes[J].J Clin Oncol,2013,31(28):3557-3564.
12 卢丹,秦亚溱,李玲娣,等.骨髓增生异常综合征患者骨髓及外周血中WT1及PRAME基因的表达研究[J].中国实验血液学杂志,2014,22(2):370-376.
13 Starmans MH,Lieuwes NG,Span PN,et al.Independent and functional validation of a multi-tumour-type proliferation signature[J].Br J Cancer,2012,107(3):508-515.
14 黄莹,文静,李虹颖,等.miR-550a-5p在骨髓增生异常综合征中的表达及其靶基因预测[J].中国实验血液学杂志,2016,24(5):1476-1483.
15 Zhou L,Mcmahon C,Bhagat T,et al.Reduced SMAD7 leads to over activation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase[J].Cancer Res,2011,71(3):955-963.
16 吕远飞,闫振宇,陈乃耀,等.淋巴细胞亚群在再生障碍性贫血和低增生性骨髓增生异常综合征患者外周血中的表达分析[J].中国实验血液学杂志,2016,24(5):1505-1510.

[1]	李林，毛朝明，周建明，高健青. ¹⁸F-FDG PET-CT显像在多发性骨髓瘤中的影像表现[J]. 实用肿瘤学杂志, 2017, 31(3): 222-227.
[2]	李文君，郭艳秋，高玉娟综述，苏雁华审校. 多发性骨髓瘤骨病的机制研究及治疗进展[J]. 实用肿瘤学杂志, 2017, 31(3): 246-249.
[3]	简立智，王天娇综述，吴瑾审校. 基质蛋白对恶性肿瘤骨转移作用的研究进展[J]. 实用肿瘤学杂志, 2017, 31(3): 285-288.
[4]	杜雅茹, 赵艳红综述, 周晋审校. 输血相关性铁过载在血液肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2017, 31(1): 78-82.
[5]	赵郁，朱晓婷，王轶楠. ω-3多不饱和脂肪酸诱导多发性骨髓瘤细胞凋亡及抗增殖机制的研究[J]. 实用肿瘤学杂志, 2016, 30(6): 516-522.
[6]	操梅林, 徐燕丽, 张磊. 多发性骨髓瘤化疗后发生急性髓系白血病一例并文献复习[J]. 实用肿瘤学杂志, 2015, 29(6): 536-539.
[7]	王燕, 刘爱春. 多发性骨髓瘤的治疗进展[J]. 实用肿瘤学杂志, 2012, 26(2): 183-187.
[8]	张依综述, 姜达审校. 间充质干细胞及其在肿瘤治疗中的应用[J]. 实用肿瘤学杂志, 2009, 23(3): 282-286.
[9]	王(王争);周义林;张军盛;徐惠琴. 多发性骨髓瘤病人99m Tc-MIBI显像的临床价值[J]. 实用肿瘤学杂志, 2008, 22(05): 441-443.
[10]	丁汀;裘小萍;顾磊;王应贵;陈峪;陈兆军;蒋挺英. 多发性骨髓瘤血小板生成素及受体初步研究[J]. 实用肿瘤学杂志, 2005, 19(03): 178-180.
[11]	钟礼瀑;吴青青;邹学森. 69例恶性淋巴瘤骨髓侵犯后骨髓象与血象分析[J]. 实用肿瘤学杂志, 2004, 18(05): 327-329.
[12]	张宇明;江黎明;陈永振. 急性髓性白血病患者骨髓基质细胞ICAM-1的检测及临床意义[J]. 实用肿瘤学杂志, 2004, 18(03): 208-210.
[13]	张旭光;刘芳;马东生;周凤娟;章龙珍;刘凌. 脐带血减缓放疗病人的骨髓功能抑制[J]. 实用肿瘤学杂志, 2003, 17(03): 206-208.
[14]	薛英威;孙迷离;刘秀华;刘立人. 5-Fu不同应用方式对大白鼠骨髓影响的观察[J]. 实用肿瘤学杂志, 2003, 17(01): 6-8.
[15]	袁志军;肖立新;欧阳沙西. 多发性骨髓瘤并发肾脏损害误诊原因分析[J]. 实用肿瘤学杂志, 2002, 16(04): 267-268.

骨髓中CDKN1C阳性表达在MDS和AML患者中检测的临床意义

Clinical significance of CDKN1C positive expression in bone marrow in patients with myelodysplastic syndrome and secondary acute myeloid leukemia

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价